Semax
A synthetic neuropeptide analog often discussed for cognitive and neuroprotection-related interest in research-market circles.
Also appears in: Immune
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Semax crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Cognitive. Also surfaces under Immune for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 0 trials · 400 PubMed results
Current evidence for Semax is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Semax has no clinical trials that name it and 400 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What semax is
Semax is a synthetic neuropeptide analog that appears in nootropic and neuroprotection conversations. It is often grouped near selank, but the two should not be treated as interchangeable.
Why it matters
This profile helps build out the cognitive side of the peptide library and makes the nootropic category feel intentional instead of token.
Regulatory context
Semax is not an FDA-approved cognitive or neurologic peptide medicine in the United States. It belongs to the research-market/nootropic side of peptide discussion.
Practical reading note
Readers should expect wide variation in claim quality here. Mechanistic interest and community demand do not automatically translate into strong clinical evidence.